Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30764714 | 0.89 | MEN1 (0.52) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL30764725 | 0.86 | SIGMAR1 (0.59) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL30764759 | 0.85 | MEN1 (0.48) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL27253505 | 0.85 | MEN1 (0.48) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL30764737 | 0.80 | HSD11B1 (0.46) | ALDH1A1L3MBTL1POLBSMN1; SMN2HSD11B1 | |
| SCHEMBL30764706 | 0.79 | L3MBTL1 (0.57) | SIGMAR1ALDH1A1L3MBTL1CACNA1GSMN1; SMN2 | |
| SCHEMBL6499343 | 0.78 | CCR8 (0.61) | KMT2AMEN1KDM4EALDH1A1PKM | |
| SCHEMBL30764720 | 0.77 | SIGMAR1 (0.60) | SIGMAR1ALDH1A1L3MBTL1SMN1; SMN2HSD11B1 | |
| SCHEMBL30764736 | 0.76 | HSD11B1 (0.49) | SIGMAR1POLBCACNA1GHSD11B1 | |
| SCHEMBL6505465 | 0.75 | CCR8 (0.58) | KMT2AMEN1KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | KMT2A 2287/4885MEN1 1468/4885SIGMAR1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.